TRK 820 clinical trials
Also written Nalfurafine Hydrochloride, Remitch® and TRK-820.
How each study uses TRK 820 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TRK 820 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 9 · Other 3
Toray Industries, Inc (3) · SK Chemicals Co., Ltd. (2) · Shandong New Time Pharmaceutical Co., LTD (1) · Immunis, Inc. (1) · Indonesia University (1) · Chinese PLA General Hospital (1) · Guangdong Provincial People's Hospital (1) · Shenyang Sunshine Pharmaceutical Co., LTD. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test TRK 820.
- Jun 2027Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal DialysisNot applicable · Guangdong Provincial People's Hospital
Studies
Open first, then newest update. How each study uses TRK 820 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated DyskinesiaNot yet recruitingPhase 1Immunis, Inc.NCT07905976Written as IMM02-KORA
- Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal DialysisRecruitingNot applicableGuangdong Provincial People's HospitalNCT07098351Written as Remitch
- Efficacy of Nalfurafine for Chronic Kidney Disease-Associated Pruritus in Twice-Weekly Hemodialysis Patients: A Randomized Controlled TrialNot yet recruitingPhase 4Indonesia UniversityNCT07769073Written as Nalfurafine Hydrochloride
- Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance HemodialysisNot yet recruitingNot applicableChinese PLA General HospitalNCT07650851Written as Nalfurafine Hydrochloride
- Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in HumansCompletedNot applicableShandong New Time Pharmaceutical Co., LTDNCT07478133Written as Remitch®
- Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving HemodialysisTerminatedPhase 2Toray Industries, IncNCT01660243Written as Nalfurafine hydrochloride(MT-9938) 2.5μg
- A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating TabletStatus unknownPhase 3Shenyang Sunshine Pharmaceutical Co., LTD.NCT04728984Written as Nalfurafine Hydrochloride
- TRK-820 Study in Subjects on Hemodialysis With or Without Uremic PruritusCompletedPhase 1Toray Industries, IncNCT03002233Written as TRK-820
- Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving HemodialysisCompletedPhase 3SK Chemicals Co., Ltd.NCT01513161Written as nalfurafine hydrochloride (TRK-820)
- Safety Study of TRK-820 for Patient With HemodialysisCompletedPhase 1SK Chemicals Co., Ltd.NCT01248650Written as nalfurafine hydrochloride
- A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)Status unknownPhase 3Acologix, Inc.NCT00793156Written as Nalfurafine HCl 2.5 µg
- Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -CompletedPhase 2Toray Industries, IncNCT00638495Written as Nalfurafine Hydrochloride (TRK-820)
As the comparator · 1 — what is tested is compared with TRK 820
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call TRK 820 · ClinicalTrials.gg INT004055
- MeSH (NLM) C111212TRK 820Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 25CC4N0P8JNALFURAFINE HYDROCHLORIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C111212 | TRK 820 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 25CC4N0P8J | NALFURAFINE HYDROCHLORIDE | Confirmed FDA, NLM |
Also registered as nalfurafine (UNII XC41AVD567).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.